Novo Nordisk (NVO) Hit By Lowered Guidance

3 weeks ago 9

Soumya Eswaran

Wed, December 17, 2025 astatine 7:57 AM CST 3 min read

GreensKeeper Asset Management, an concern absorption company, released its third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Value Fund has ended the 4th with a +4.0% gain, taking the YTD instrumentality to +0.2% nett of fees and expenses. The US dollar continued to airs a challenge, negatively impacting show by -3.7% truthful acold this year. The year’s marketplace rally was chiefly led by AI, crypto, and speculation. In addition, you tin cheque the fund’s apical 5 holdings to find its champion picks for 2025.

In its third-quarter 2025 capitalist letter, GreensKeeper Asset Management highlighted stocks specified arsenic Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages successful the probe and development, manufacture, and organisation of pharmaceutical products. The one-month instrumentality of Novo Nordisk A/S (NYSE:NVO) was -0.08%, and its shares mislaid 53.79% of their worth implicit the past 52 weeks. On December 16, 2025, Novo Nordisk A/S (NYSE:NVO) banal closed astatine $48.96 per share, with a marketplace capitalization of $217.553 billion.

GreensKeeper Asset Management stated the pursuing regarding Novo Nordisk A/S (NYSE:NVO) successful its 3rd 4th 2025 capitalist letter:

"Our second-largest detractor successful the 4th was Novo Nordisk A/S (NYSE:NVO) -19.6%. NVO lowered its guidance owed to respective factors, including persistent usage of compounded GLP-1 medications, slower-than-expected marketplace enlargement for obesity treatments, and heightened contention from Eli-Lilly’s tirzepatide-based therapies. We invited the precocious announced changes to elder absorption and the company’s caller absorption connected operating efficiency.

Novo Nordisk A/S (NYSE:NVO) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 50 hedge money portfolios held Novo Nordisk A/S (NYSE:NVO) astatine the extremity of the 3rd quarter, which was 45 successful the erstwhile quarter. While we admit the imaginable of Novo Nordisk A/S (NYSE:NVO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.